Bovie Medical Corporation (the “Company”) (NYSE Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced that Jeff Rencher, Vice President of Sales and Marketing of Surgical Products, will host a conference call at 11:00 am EDST on Thursday, November 1st to discuss Bovie’s J-Plasma technology.
Mr. Rencher will be joined on the call by Dr. Royce Adkins, MD, FACOG, an expert in women’s health who is regularly listed as one of “America’s Top Obstetricians and Gynecologist” by Who’s Who’s Best Doctors in America®.” Dr. Adkins is affiliated with Tennessee Women's Care in Nashville. A board-certified Ob/Gyn, he holds hospital privileges at Baptist Hospital and Centennial Medical Center in Nashville, and he also serves as Clinical Instructor of OB-GYN at Vanderbilt University Medical Center.
Shareholders and interested parties may participate in the call by dialing 1 (866) 639-9991 or 1-678-302-3571. Please call a few minutes before the conference call is scheduled to begin. A recording of the live conference call will be immediately available after the call has concluded for the next 30 days. The dial-in number to listen to the recording is 1 (866) 510-4862 or 1-678-302-3562 then enter access code 4804300#. Press 4 to listen and enter the confirmation number 201109205106963#.
Dr. Adkins is an avid researcher, participating as subinvestigator for numerous studies on such topics as hypertension in pregnancy, endometriosis, preterm labor, contraception, vaginal atrophy, osteoporosis, HRT, migraine, bacterial vaginosis, yeast infections, genital herpes, libido disorders, menstrual bleeding and hysteroscopic sterilization. He is a frequent speaker at the National ACOG and AAGL annual meetings, having most recently presented on "Evaluating the NovaSure® System for Endometrial Ablation in Patients with a History of C-Section," and on "Adiana®Hysteroscopic Tubal Occlusion." He has published on various subjects in Obstetrics and Gynecology. He has also lectured locally and nationally at Universities, hospitals, clinics, and industry-sponsored speakers' bureaus. Dr. Adkins performed the first office-based NovaSure® procedure in the Southeast, and he is experienced with all types of second-generation endometrial ablation technologies. Dr. Adkins has over 25 years experience with Urogynecology procedures and Pelvic Floor disorders in general. Dr. Adkins and his colleague Dr. Bressman also performed the first Renessa® procedure in Tennessee.
Dr. Adkins is active in AAGL-Advancing Minimally Invasive Gynecology Worldwide and performed the 1st single site laparoscopy at Centennial Medical Center in 2010.
In other news, the Company announced it will be attending and presenting J-Plasma™ at the 41st AAGL Global Congress on minimally invasive gynecology November 5-9th in Las Vegas, Nevada. The AAGL conference is attended annually by over 3,000 gynecologists from throughout the world.
Cautionary Note on Forward-Looking Statements
Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.
Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Report on Form 10-K for the year ended December 31, 2011. For forward-looking statements in this new release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemedical.com.Business Wire
Last updated on: 23/10/2012